Hui Zhou

Safety and activity of sintilimab in patients with relapsed or refractory classical Hodgkin lymphoma (ORIENT-1): a multicentre, single-arm, phase 2 trial

Yuankai Shi, Hang Su, Yongping Song et al. · The Lancet Haematology · 2019 · 249 citations

Life Sciences, Immunology, Oncology +7

Combination of anti-PD-1 antibody with P-GEMOX as a potentially effective immunochemotherapy for advanced natural killer/T cell lymphoma

Jun Cai, Panpan Liu, Huiqiang Huang et al. · Signal Transduction and Targeted Therapy · 2020 · 83 citations · Full text

Medicine, Hematology, Oncology +17

CMR imaging biosignature of cardiac involvement due to cancer-related treatment by T1 and T2 mapping

Jasmin D. Haslbauer, Sarah Lindner, Silvia Valbuena-López et al. · International Journal of Cardiology · 2018 · 72 citations · Full text

Medicine, Oncology, Radiology +15

Native T1 and T2 provide distinctive signatures in hypertrophic cardiac conditions – Comparison of uremic, hypertensive and hypertrophic cardiomyopathy

Luca Arcari, Rocío Hinojar, Juergen Engel et al. · International Journal of Cardiology · 2020 · 64 citations · Full text

Medicine, Cardiology, Radiology +16

Efficacy and safety of geptanolimab (GB226) for relapsed or refractory peripheral T cell lymphoma: an open-label phase 2 study (Gxplore-002)

Yuankai Shi, Jianqiu Wu, Zhen Wang et al. · Journal of Hematology & Oncology · 2021 · 63 citations · Full text

Pharmacy, Oncology, Pharmacotherapy +17